FDA Ad Policies Will Be One Issue In Commissioner Confirmation Process
Executive Summary
FDA's reconsideration of its authority to regulate drug promotions under the First Amendment is one issue FDA Commissioner nominee Mark McClellan is likely to face during Senate confirmation hearings
You may also be interested in...
RU-486 safety profile
FDA has "received a few letters about RU-486 expressing concerns about potential new safety risks," Commissioner McClellan says during National Press Club address Aug. 8. "We are carefully evaluating all of that information." The abortifacient is marketed by Danco as Mifeprex; the Bush Administration's theme since taking office has been that FDA will keep an eye on the safety of the drug as it would for any other marketed product (1"The Pink Sheet" Sept. 30, 2002, p. 6)...
RU-486 safety profile
FDA has "received a few letters about RU-486 expressing concerns about potential new safety risks," Commissioner McClellan says during National Press Club address Aug. 8. "We are carefully evaluating all of that information." The abortifacient is marketed by Danco as Mifeprex; the Bush Administration's theme since taking office has been that FDA will keep an eye on the safety of the drug as it would for any other marketed product (1"The Pink Sheet" Sept. 30, 2002, p. 6)...
DTC Is Not Improving, Rep. Waxman Says: Viagra Ads Show “Six” Sells?
The decline in advertising enforcement actions by FDA does not reflect better compliance in direct-to-consumer advertisements, House Government Reform Committee Ranking Member Henry Waxman (D-Calif.) maintains